Mayerhoefer, M. E., Staudenherz, A., Kiesewetter, B., Weber, M., Simonitsch-Klupp, I., Gibbs, P., . . . Raderer, M. (2019). Pre-Therapeutic Total Lesion Glycolysis on [(18)F]FDG-PET Enables Prognostication of 2 Year Progression-Fee Survival in MALT Lymphoma Patients Treated with CD20-Antibody-Based Immunotherapy. Mol Imaging Biol.
Styl ChicagoMayerhoefer, Marius E., Anton Staudenherz, Barbara Kiesewetter, Michael Weber, Ingrid Simonitsch-Klupp, Peter Gibbs, Werner Dolak, Julius Lukas, a Markus Raderer. "Pre-Therapeutic Total Lesion Glycolysis On [(18)F]FDG-PET Enables Prognostication of 2 Year Progression-Fee Survival in MALT Lymphoma Patients Treated With CD20-Antibody-Based Immunotherapy." Mol Imaging Biol 2019.
Citace podle MLAMayerhoefer, Marius E., et al. "Pre-Therapeutic Total Lesion Glycolysis On [(18)F]FDG-PET Enables Prognostication of 2 Year Progression-Fee Survival in MALT Lymphoma Patients Treated With CD20-Antibody-Based Immunotherapy." Mol Imaging Biol 2019.